The U.S. Food and Drug Administration has granted Fast Track Designation to a new drug combination for metastatic colorectal cancer, following encouraging results from a clinical trial led in part by the University of Oklahoma Health Stephenson Cancer …
Researchers from Rutgers Cancer Institute, New Jersey’s only National Cancer Institute (NCI)—designated Comprehensive Cancer Center, and RWJBarnabas Health, along with colleagues from the National Cancer Institute, a center of the National Institutes o…
While some risk factors for cancer can be mitigated through lifestyle choices such as diet or exercise, aging is not one of them. In the case of pancreatic cancer, it also can limit treatment options if a patient is too frail to be safely treated with …
A new radioimmunotherapy approach has the potential to cure human epidermal growth factor receptor 2 (HER2)-positive breast cancer, according to new research published in the November issue of The Journal of Nuclear Medicine. The regimen, which pre-tre…
Early data from a Phase 2 clinical trial show a combination of immunotherapy medications can activate a robust immune response and help overcome treatment resistance in patients with refractory melanoma.
New research reveals a drug developed by scientists at Oregon Health & Science University may develop into a new treatment for an especially aggressive form of breast cancer.
Colorectal cancer is one of the leading causes of cancer death worldwide. In recent years, immunotherapies—treatments that reactivate the immune system to attack tumor cells—have transformed the treatment of many types of cancer. However, most patients…
Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the Western Hemisphere, affecting approximately 200,000 people in the United States.
The gene p53 acts as a tumor suppressor and is often called the guardian of the genome. This gene is central to maintaining genomic stability, which prevents mutations from accumulating and leading to cancer. But when p53 mutates, it can flip from prot…
In preclinical studies, researchers at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, have tested a new combination therapy for hormone-resistant, estrogen receptor-positive (ER+) breast cancer and wer…
